Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. (Q34541899)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27699253%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

title

Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27699253%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27699253%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

author name string

Julian Mackay-Wiggan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27699253%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Nhan Nguyen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27699253%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Jane E Cerise

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27699253%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Charlotte Clark

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27699253%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Grace Ulerio

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27699253%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Megan Furniss

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27699253%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Roger Vaughan

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27699253%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Angela M Christiano

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27699253%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

Raphael Clynes

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27699253%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

publication date

22 September 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27699253%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27699253%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27699253%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27699253%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

page(s)

e89790

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27699253%20AND%20SRC:MED&resulttype=core&format=json

Molecular signatures define alopecia areata subtypes and transcriptional biomarkers

24 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA).

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

Genome-wide association study in alopecia areata implicates both innate and adaptive immunity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

Alopecia areata update: part II. Treatment

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

Interventions for alopecia areata

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly

7 July 2018

3 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

27 October 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

9 December 2018

12 December 2020

Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

Subcutaneous efalizumab is not effective in the treatment of alopecia areata

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033756

Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis

27 October 2018

1 reference

PubMed

12 December 2020

Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study

1 reference

PubMed

12 December 2020

Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata

1 reference

PubMed

12 December 2020

10.1172/JCI.INSIGHT.89790

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27699253%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27699253%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

1 reference